WO2000030670A1 - Effects of gdnf and ngf on sodium channels in drg neurons - Google Patents
Effects of gdnf and ngf on sodium channels in drg neurons Download PDFInfo
- Publication number
- WO2000030670A1 WO2000030670A1 PCT/US1999/027368 US9927368W WO0030670A1 WO 2000030670 A1 WO2000030670 A1 WO 2000030670A1 US 9927368 W US9927368 W US 9927368W WO 0030670 A1 WO0030670 A1 WO 0030670A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neurons
- gdnf
- ttx
- nan
- sns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
Definitions
- Provision Application 60/109,666 entitled “Differential Role of GDNF and NGF in the Maintenance of Two TTX-Resistant Sodium Channels in Adult DRG Neurons,” filed on November 20, 1998, all of which are herein incorporated by reference in their entirety.
- the present invention relates to the role of glial-derived nerve factor (GDNF) and Nerve Growth Factor (NGF) in modulating the activity of tetrodotoxin (TTX)-resistant sodium channels in dorsal root ganglion (DRG) neurons.
- GDNF glial-derived nerve factor
- NGF Nerve Growth Factor
- DRG Small dorsal root ganglion
- Transcripts for two TTX-R sodium channels, SNS/PN3 and NaN are preferentially expressed in small DRG neurons (Akopian et al., 1996; Sangameswaran et al., 1996; Dib-Hajj et al., 1998b), and may be responsible for the TTX-R sodium current observed in the soma (Kostyuk et al., 1981; Bossou and Feltz, 1984; McLean et al., 1988; Caffrey et al., 1992; Roy and Narahashi, 1992) and c-fibers (Quasthoff et al., 1995) of these neurons.
- TTX-R sodium currents in DRG neurons are attenuated (Rizzo et al., 1995; Cummins and Waxman, 1997) and concomitantly SNS/PN3 (Dib-Hajj et al., 1996; Okuse et al., 1997) and NaN (Dib-Hajj et al., 1998b) transcripts are down-regulated.
- Axotomy prevents the retrograde transport of nerve growth factor (NGF) from peripheral targets and this may account for many of the phenotypic changes that appear in DRG neurons following axotomy (for review see Verge et al., 1996).
- NGF nerve growth factor
- NGF neurotrophins other than NGF regulate the expression of TTX-R sodium channels in the subpopulation of DRG neurons that lack receptors for NGF.
- Glial cell line-derived neurotrophic factor (GDNF) has been suggested to be important for the maintenance of phenotypic properties in the subset of small sensory neurons that lack NGF receptors (Molliver et al., 1997; Bennett et al., 1998b), and intrathecal administration of GDNF can ameliorate the reduction in conduction velocity in small-diameter axons after sciatic nerve transection (Bennett et al., 1998b).
- IB4 + and IB4 " neurons express the receptor/transducing elements necessary to respond to GDNF whereas IB4 " neurons generally express the NGF receptors, TrkA and p75 (Averill et al., 1995; Wright and Snider, 1995; Bennett et al., 1996; Molliver et al, 1997; Bennett et al., 1998b).
- TrkA and p75 Basill et al., 1995; Wright and Snider, 1995; Bennett et al., 1996; Molliver et al, 1997; Bennett et al., 1998b.
- IB4 + and IB4 " neurons Based on differences in terminal fields in the spinal cord and certain differences in phenotype of IB4 + and IB4 " neurons, it has been suggested that these two subpopulations of small DRG neurons may play distinct roles in nociceptive transmission (see Snider and McMahon, 1998).
- the present invention provides a new means of altering or modulating inappropriate electrical activity which may be involved in pain syndromes.
- the present invention includes a method to treat pain or hyperexcitabihty phenomena in an animal or human subject by administering an amount of GDNF or GDNF-related molecule that is effective to alter TTX-R Na + current flow through NaN sodium channels in sensory neurons such as DRG or trigeminal neurons.
- the present invention also includes a method to treat pain, paraesthesia or hyperexcitabihty phenomena in an animal or human subject by administering an effective amount of GDNF or a GDNF-related molecule that is capable of at least partially restoring the normal balance between various types of TTX-R and TTX-S sodium channels in sensory neurons such as DRG or trigeminal neurons.
- the invention includes a method to treat pain, paraesthesia or hyperexcitabihty phenomena in an animal or human subject by administering an effective amount of an agent capable of modulating the transcription or translation of mRNA encoding sodium channels selected from the group consisting of SNS/PN3 and NaN channels.
- agents includes neurotrophins such as NGF and GDNF.
- the invention includes a method to treat pain, paraesthesia or hyperexcitabihty phenomena in an animal or human subject by administering an effective amount of an agent capable of altering the transcription or translation of mRNA encoding the NaN sodium channel.
- Another aspect of the invention includes a method of identifying an agent which modulates TTX-R Na + current through NaN channels comprising the step of determining whether the agent alters or modulates the expression of GDNF or at least one biological activity of GDNF.
- the invention includes a method to screen candidate compounds for use in treating pain and hyperexcitabihty phenomena comprising the steps of exposing the cell to the compound in the presence or absence of GDNF and determining the resultant level of expression or activity of the cell's Na + channels.
- FIG. 1 SNS/PN3 and NaN mRNA in representative LB4 + and IB4 DRG neurons.
- LB4 binding visualized using biotin-labeled LB4 and Cy2-labeled streptavidin, can be readily recognized after in situ hybridization. Examples of 1 day in vitro ("DIN") neurons processed for in situ hybridization and IB4-binding are shown.
- A,C IB4 positivity and negativity after S ⁇ S P ⁇ 3 in situ hybridization.
- B,D Corresponding Nomarski images of the same neurons.
- SNS/PN3 mRNA is expressed in both IB4 + (A,B) and IB4 " (C,D) DRG neurons.
- E,G IB4 binding after NaN in situ hybridization.
- FIG. 3 SNS/PN3 (A) and NaN (B) distribution in small ( ⁇ 30 ⁇ m) IB4 + and IB4 " neurons.
- A,B Frequency diagram showing the percentage of IB4 + and LB4 " neurons, respectively, within each hybridization intensity bin (bin-width 0.4 unit). The percentage of neurons is plotted at the midpoint of each bin. The relative intensity was calculated by subtracting the background intensity and then dividing the optical density of each neurons by the mean of all neurons examined in that experiment. Data was pooled from four independent experiments.
- A) SNS/PN3 mRNA is expressed in both in IB4 + and IB4 " DRG neurons. Note that the most intensely stained cells (relative intensity >2.0) were almost exclusively IB4 " .
- FIG. 4 Comparison of sodium currents in IB4 + and IB4 " DRG neurons.
- Two current components can be easily resolved in the left and middle panels; a slowly inactivating component that has a relatively depolarized voltage-dependence of inactivation (N h ) and a fast inactivating component that has a more negative V h .
- the steady-state inactivation curves for these cells are bimodal because of the different inactivation properties of the two components (arrows indicate point of inflection).
- FIG. 5 Comparison of TTX-R currents in LB4 + and IB4 " neurons.
- the currents were elicited by 200 ms test pulses ranging from -80 to +40 mV in 5 mV steps. Cells were held at -100 mV.
- FIG. 7 SNS/PN3 in situ hybridization of representative IB4 + and IB4" DRG neurons after treatment with NGF and GDNF for 7 days. Without addition of either growth factor, little hybridization signal is seen in either IB4 + A) or IB4 " (B) neurons. NGF increases the signal in both IB4 + (C) and IB4 " (D) neurons. GDNF increased the hybridization signal predominantly in LB4 + neurons (E), with little effect on IB4 " neurons (F). Scale bar is 25 ⁇ m.
- FIG. 8 The upregulation of SNS/PN3 mRNA by NGF is blocked by K252a.
- Each bar represents the mean of the pooled, normalized optical densities from 2 to 4 independent experiments. Error bars represent standard error.
- *The SNS PN3 hybridization signal was significantly (p c ⁇ 0.001; Bonferroni t test) less intense in neurons treated with both NGF and K252a compared to neurons treated with NGF alone.
- FIG. 9 Effects of neurotrophins on the expression of NaN mRNA. Data from three different experiments are normalized and pooled. The graph represents the mean normalized OD for IB4 + and IB4 ⁇ neurons respectively for each condition. Error bar represents standard error. At 7 DIN the ⁇ a ⁇ hybridization signal was significantly reduced in IB4 + neurons. GD ⁇ F increased the ⁇ a ⁇ hybridization signal in IB4 + neurons, but had no effect on in IB4 " neurons. ⁇ GF did not increase ⁇ a ⁇ expression in either IB4 + or IB4 " neurons. * Significantly different from 7 DIN control by Bonferroni t test for multiple comparisons (p c ⁇ 0.001).
- FIG 10. ⁇ a ⁇ in situ hybridization of LB4 ⁇ and IB4 " DRG neurons after treatment with ⁇ GF and GD ⁇ F for 7 days. Without addition of either growth factor, little hybridization signal is seen in either IB4 + A) or IB4 " (B) neurons. ⁇ GF did not increase the signal in either IB4 + (C) or IB4 " (D) neurons. GD ⁇ F increased the hybridization signal markedly in IB4 + neurons (E), but had no effect on IB4 " neurons (F). Scale bar is 25 ⁇ m. Figure 11. GD ⁇ F increases TTX-R currents in cultured DRG neurons. A) Families of voltage-activated TTX-R current traces recorded from representative DRG neurons.
- Figure 12A shows families of voltage-activated TTX-R current traces recorded from representative S ⁇ S-null neurons after 1 day in vitro (IDIN), untreated S ⁇ S- null neurons after 7 days in vitro (IDIN) and GD ⁇ F-treated S ⁇ S-null neurons after 7 days in vitro (DIN).
- Figure 12B shows TTX-R peak current amplitude from IDIN, untreated 7DIN, GD ⁇ F-treated 7DIV and ⁇ GF-treated 7DIV S ⁇ S-null neurons.
- Figure 13 A shows that GD ⁇ F administration attenuates the decrease in current density that results from axotomy.
- Figure 13B shows that GD ⁇ F administration attenuates the decrease in persistent ⁇ a + currents that results from axotomy.
- TTX-R sodium currents Following axotomy, electrophysiological properties of small dorsal root ganglion (DRG) neurons are markedly altered, with attenuation of TTX-R sodium currents and the appearance of rapidly reprinting TTX-S currents.
- the reduction in TTX-R currents has been attributed to a down-regulation of sodium channels SNS/PN3 and NaN. While infusion of exogenous NGF to the transected nerve restores SNS/PN3 transcripts to near- normal levels in small DRG neurons, TTX-R sodium currents are only partially rescued.
- Binding of the isolectin IB4 distinguishes between two major subpopulations of small DRG neurons: IB4 + neurons, which express receptors for the GDNF family of neurotrophins, and LB4" neurons that predominantly express trkA.
- SNS/PN3 is expressed in approximately one-half of both IB4 + and IB4 " DRG neurons, while NaN is preferentially expressed in IB4 + neurons.
- Whole-cell patch-clamp studies demonstrate that TTX-R sodium currents in IB4 + neurons have a more hyperpolarized voltage-dependence of activation and inactivation than do IB4 " neurons, suggesting different electrophysiological properties for SNS/PN3 and NaN.
- NGF restores SNS/PN3 mRNA levels and demonstrate that the trk antagonist K252a blocks this rescue, indicating a central role for trkA receptors in the signaling pathway.
- DRG neurons exhibit at least two distinct types of TTX-R currents based on the voltage-dependence of activation and inactivation (Brau and Elliott, 1998; Rush et al, 1998; Scholz et al., 1998).
- the present inventors' results indicate that NaN and SNS/PN3 could underlie these distinct TTX-R currents in small DRG neurons.
- Expression of SNS/PN3 in Xenopus oocytes gives rise to voltage-gated sodium currents with slow kinetics and resistance to high concentrations of TTX (Akopian et al., 1996; Sangameswaran et al, 1996).
- nociceptive neurons might fine-tune their integrative and repetitive firing properties by altering the relative expression of SNS/PN3 and NaN channels. These channels may also differ in other properties, such as subcellular localization and sensitivity to second messenger modulation, which could also be important determinants of transductive and/or encoding characteristics of different DRG neurons.
- IB4 + neurons expressed slow TTX-R currents that were similar to the TTX- R2 currents described by Rush et al. (1998); on the other hand, the TTX-R1 currents were similar to the predominant TTX-R current in IB4 " cells.
- Fast TTX-R currents such as those described by Scholz et al. (1998) in either IB4 + or IB4 " cells were not observed.
- IB4 " group about one-third of the small neurons had very low amplitude, or no TTX-R currents, suggesting that this group of neurons expressed neither SNS/PN3 nor NaN.
- This subpopulation of LB4 " neurons, which expressed relatively large fast TTX-S currents, may represent a distinct subset of sensory neurons.
- NGF has previously been shown to play a prominent role in the regulation of sodium channel/current expression in PC 12 cells, as well as DRG neurons.
- NGF up-regulates sodium channels II and PN1 through distinct signal transduction pathways, with the latter being Ras-independent (D'Arcangelo et al., 1993).
- short-term (1-minute) application of NGF up-regulates PN1 but not brain type II in PC12 cells (Toledo-Aral et al, 1995).
- NGF application accelerates the diversity and acquisition of sodium currents in neonatal DRG neurons (Omri and Meiri, 1990) and increases the threshold for spike generation in young post-natal DRG neurons (Aguayo and White, 1992).
- the role of NGF in the regulation of SNS/PN3 mRNA in DRG neurons has been the focus of several studies. Administration of exogenous NGF increases the levels of SNS/PN3 mRNA both in vitro and in vivo (Black et al., 1997; Dib-Hajj et al., 1998a; this study).
- SNS/PN3 mRNA seen in LB4 + neurons after treatment with NGF may reflect an effect on those neurons that also express trkA.
- NGF does not regulate the expression of all sodium channel mRNAs in DRG neurons that express TrkA receptors, as NGF had no detectable effect on NaN mRNA expression.
- GDNF has well-established roles as a potent survival factor for certain classes of neurons (Lin et al., 1993; Henderson et al., 1994; Oppenheim et al., 1995; Yan et al., 1995) and as a protector of neurons from injury (Tomac et al., 1995; Beck et al., 1995), the effect of this neurotrophin on the electrical properties of neurons is largely unknown.
- NGF and GDNF share several characteristics as target-derived, retrogradely- transported neurotrophic factors.
- NGF is primarily expressed in the skin; the levels of NGF are increased in inflamed tissues, and both endogenous and exogenous increase of tissue NGF levels are associated with pain hyperalgesia (Lewin et al., 1994; Woolf, 1996; Woolf et al., 1996; Dyck et al., 1997).
- NGF-deprivation in vivo prevents hypersensitivity and results in thermal hypoalgesia (Chudler et al., 1997; Bennett et al., 1998a).
- GDNF is produced at very low levels in adult skin and 5 spinal cord, but is expressed by Schwann cells in the sciatic nerve (Nosrat et al., 1996; Widenfalk et al., 1997), suggesting that Schwann cells may be the primary source of GDNF for adult DRG neurons. It has been suggested that an up-regulation of GDNF in the injured nerve may play an important role for regeneration of sensory neurons following axotomy (Trupp et al., 1995; Hammarberg et al, 1996; Naveilhan et al., 1997; Bar et al.,
- NGF increases the expression of SNS/PN3, but not NaN mRNA
- SNS/PN3 may encode a TTX-R sodium current with a more depolarized inactivation curve and a higher threshold for activation. Changes in the levels of NGF and GDNF 0 might therefore affect the elecfrogenic properties of some small DRG neurons after nerve injury, possibly contributing to the development of hyperexcitibility.
- alter refers to up- or down-regulating the levels or activity of NaN, such as current flow.
- a model cultured cell line that expresses the NaN sodium channel and GDNF or a GDNF receptor is utilized, and one or more
- conventional assays are used to measure Na + current.
- Such conventional assays include, for example, patch clamp methods, the ratiometric imaging of [Na + ],-, and the use of 22 Na and 86 Rb.
- the amount of NaN RNA or protein may be directly measured by conventional assays such as hybridization of immunoblot assays.
- an agent is brought into contact with a suitable transformed host cell that expresses a functional GDNF receptor and NaN or GDNF.
- a suitable transformed host cell that expresses a functional GDNF receptor and NaN or GDNF.
- Cells that express endogenous NaN are also useful for screening of candidate agents.
- the Na + current is measured to determine if the agent inhibited or enhanced Na + current flow. If the cell line is engineered to express a functional GDNF receptor, the agent to be tested may be brought into contact with a suitable host cell in the presence or absence of exogenously supplied GDNF. Agents that inhibit or enhance Na + current are thereby identified.
- the preferred agents that alter or modulate the levels or activity of NaN preferably will be selective for the NaN Na + channel, may be selective for GDNF or may alter or modulate the GDNF mediated induction of NaN.
- Similar analyses may be conducted by the skilled artisan to identify agents that alter the effect of other neurotrophic factors. For example, Mildbrandt, J. et al.. (Neuron, vol. 20, 245-253) describes the discovery of a third member of the GDNF family, Persephin, and reviews the literature on this family. The other two members are: GDNF (the prototype) and nurturin (NTN). Four receptors for these ligands have been identified.
- Agents of the invention may be totally specific (like tetrodotoxin, TTX, which inhibits sodium channels but does not bind to or directly effect any other channels or receptors), or relatively specific (such as lidocaine which binds to and blocks several types of ion channels, but has a preference for sodium channels).
- Total specificity is not required for an inhibitor or enhancer to be effective; the ratio of its effect on sodium channels vs. other channels and receptors, will determine its effect; and effects on several channels, in addition to the targeted one, may be of interest.
- modulating agents of the present invention can be, as examples, peptides, small molecules, naturally occurring or synthetic toxins and vitamin derivatives, as well as carbohydrates.
- a skilled artisan will readily recognize that there is no limit as to the structural nature of the modulating agents of the present invention. It is contemplated that the screening of libraries of molecules will reveal agents that modulate NaN or current flow through it.
- agents of the present invention are peptide agents whose amino acid sequences are chosen based on the amino acid sequence of the of the NaN Na + channel, of GDNF or a functional GDNF receptor. Such peptide fragments can be routinely identified by exposing a transformed host cell to these agents and measuring any resultant changes in Na + current.
- naturally occurring toxins such as those produced by certain fish, amphibians and invertebrates
- Agents of the invention may be administered to a human or animal subject.
- a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by the alteration or modulation of sodium channels such as NaN.
- the term "mammal” is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.
- Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, alteration or the modulation of the amount or of a biological activity of NaN may be associated with pain, paraesthesia or hyperexcitabihty phenomena.
- an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, pain, paraesthesia or hyperexcitabihty phenomena may be prevented, altered or modulated by the administration of agents which reduce, enhance or modulate in some way GDNF induction ofNaN.
- agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process.
- an agent of the present invention such as GDNF, a GDNF-related molecule such as a GDNF peptide, or a NaN peptide can be administered in combination with another agent that alters or modulates Na + current.
- two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.
- the agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100 ⁇ g/kg body wt. The preferred dosages comprise 0.1 to 10 ⁇ g/kg body wt. The most preferred dosages comprise 0.1 to 1 ⁇ g/kg body wt.
- compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action.
- suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dexfran.
- the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.
- the pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.
- Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.
- the DRGs were gently centrifuged (lOOg for 3 min.) and the pellet triturated in DRG-media (DMEM:F12, 10% FCS) containing lmg/ml bovine-serum albumin (BSA, Fraction V) (Sigma, St. Louis, MO) and 1 mg/ml trypsin inhibitor (Sigma).
- DRG-media DRG-media
- BSA bovine-serum albumin
- trypsin inhibitor Sigma
- DRG media DRG media supplemented with NGF (50 ng/ml, mouse 7S NGF, Sigma), GDNF (human recombinant, 50 ng/ml, Calbiochem, San Diego, CA), BDNF (10ng/ml, Regeneron) or DRG media supplemented with a combination of NGF (50 ng/ml) and GDNF (50 ng/ml).
- NGF 50 ng/ml, mouse 7S NGF, Sigma
- GDNF human recombinant, 50 ng/ml, Calbiochem, San Diego, CA
- BDNF 10ng/ml, Regeneron
- DRG media DRG media supplemented with a combination of NGF (50 ng/ml) and GDNF (50 ng/ml).
- the cells were maintained in culture for seven days and one-half of the media was replaced daily.
- trk inhibitor K252a was used to determine if the effect of NGF on SNS/PN3 mRNA expression is mediated through the trkA pathway.
- K252a (Calbiochem) was dissolved in DMSO (lmg/ml) and added to cultures in concentrations ranging from 100 nM - 400 nM.
- SNS/PN3 and NaN mRNA in individual neurons was determined by in situ hybridization as previously described (Black et al., 1996; Dib-Hajj et al., 1998b). In short, coverslips from the different experimental groups were fixed for 10 min. in 4% formaldehyde in 0.14M Sorensons buffer, pH 7.2, washed several times with diethylpyrocarbonate (DEPC) -treated PBS and permeabilized with 0.1 % Triton X-100 in PBS for 15 min.
- DEPC diethylpyrocarbonate
- the coverslips were then rinsed with 2X SSC, prehybridized for 30 min and then hybridized at 58°C overnight using riboprobes (0.25-0.5 ng/ml) specific for SNS/PN3 or NaN.
- the coverslips were sequentially incubated in 4X SSC, 2X SSC, RNase A (20mg/ml; Sigma; 37°C, 30 min.) and finally 0.2X SSC at 58°C for 3 X 20 min.
- coverslips were then blocked with 2% normal sheep serum and 1 % BSA for 20 min and incubated with alkaline phosphates-conjugated anti-digoxigenin F'ab fragments (1 :500, Boerhinger-Mannheim) overnight at 4°C. Following multiple rinses, the hybridization signal was visualized using NBT histochemistry. Coverslips for each condition in each experiment were kept in the NBT solution for the same length of time; the NBT reaction was monitored visually and stopped before the signal reached saturation.
- IB4 biotin labeled- isolectin B4
- coverslips were incubated with streptavidin-Cy2 (40 ⁇ g/ml, Amersham Life Science Inc, Arlington Heights, IL) and alkaline phosphatase-conjugated anti-digoxigenin antibody (1:500, Boerhinger-Mannheim) in Tris-buffered blocking solution (1% BSA, 2% normal goat serum) overnight at 4°C.
- Samples for analysis were obtained from each coverslip by arbitrarily scrolling the coverslip from the upper left quadrant and capturing the first twenty to fifty fields containing distinguishable neurons.
- the neurons in the captured images were outlined and the area and mean optical density of each cell was determined.
- the optical densities were normalized by dividing the OD of each neuron by the mean SNS/PN3 or NaN optical density of the control cells at 1 DIN, processed in the same in situ hybridization experiment.
- the OD of each IB4 + or IB4 " neuron was normalized as described above using the mean optical density of all (IB4 + and LB4 " ) neurons.
- Neurons were considered positive for SNS/PN3 or NaN if the relative intensity was > 0.8, which corresponds to a lightly stained neuron.
- K252a added to the medium, the mean OD of all neurons from cultures that had not received any supplement was used to normalize the experimental values.
- the Mann- Whitney Rank sum test was used to test if statistically significant differences exist in the expression of SNS/PN3 and NaN mRNA in IB4 + and IB4 " neurons.
- the means of the normalized optical densities pooled from 3 separate experiments were analyzed using a one-way ANON A. If a significant difference was detected, a two-tailed Student t test was used and the resulting p-value was corrected by multiplying by the number of comparisons made (Bonferroni t test). Significance was assessed as/7 correc , e (p c ) ⁇ 0.05.
- the standard extracellular solution contained (in mM): 140 ⁇ aCl, 3 KCl, 2 MgCl 2 , 1 CaCl 2 , 0.1 CdCl 2 , and 10 HEPES (pH 7.3). Cadmium was included to block calcium currents. The osmolarity of the solutions was adjusted to 310 mosM (Wescor 5550 osmometer). The liquid junction potential for these solutions was ⁇ 7 mV; data were not corrected to account for this offset. The offset potential was zeroed before patching the cells and checked after each recording for drift. All recordings were conducted at room temperature (-22° C).
- Example 1 SNS/PN3 and NaN mRNA in IB4 + and IB4 DRG neurons Both S ⁇ S/P ⁇ 3 and NaN mRNA are suggested to encode TTX-R sodium channels in DRG neurons (Akopian et al., 1996; Sangameswaran et al., 1996; Dib-Hajj et al., 1998b), and both are preferentially expressed in small ( ⁇ 30 ⁇ m) DRG neurons (Fig. 1).
- Small DRG neurons have been differentiated into two major subpopulations on the basis of their ability to bind to the lectin LB4 (Averill et al., 1995; Wright and Snider, 1995; Molliver et al., 1997; Bennett et al., 1998b).
- LB4 lectin-binding protein
- SNS/PN3 mRNA was expressed in both IB4 + and IB4 " neurons, but neurons with the greatest hybridization signal for SNS/PN3 mRNA were predominantly IB4 " .
- the difference in SNS/PN3 mRNA expression between IB4 + and IB4 " neurons was significant (p ⁇ 0.05, Mann- Whitney rank sum test) (Fig. 3a).
- NaN was expressed predominantly in LB4 + neurons (p ⁇ 0.0001, Mann- Whitney rank sum test) (Fig.
- Example 2 TTX-R currents in IB4 + and IB4 ⁇ neurons
- neurons were assigned to one of three groups: IB4 + neurons with both fast and slow currents (IB4 + F/S), IB4 " neurons with both fast and slow currents (IB4 ⁇ F/S), and IB4 " neurons with only fast currents (IB4 " F) (Fig. 4A).
- Prepulse-inactivation was used (McLean et al., 1988; Roy and Narahashi, 1992; Elliott and Elliott, 1993; Cummins and Waxman, 1997) to separate fast and slow sodium current components in the cells.
- the peak amplitudes for fast and slow sodium current components are compared in Table 1.
- the slow current peak amplitude was similar for IB4 + F/S and IB4 F/S cells, but the fast current amplitude was smaller for IB4 + F/S cells than for the IB4 " F/S cells.
- DRG neurons studied in the presence of 250 nM TTX can also be subdivided into three groups: IB4 + with TTX-R sodium current, IB4 " with TTX-R sodium current and LB4 " without TTX-R sodium current (Fig. 5A, Table 1).
- the amplitude of the TTX-R current was similar for the IB4 + and LB4 " groups that expressed sodium currents.
- ⁇ h The rate of inactivation ( ⁇ h ) for the TTX-R sodium currents in the IB4 + and LB4" cells was compared.
- ⁇ h was longer in LB4 " cells than in IB4 + cells, all of the TTX-R currents in both groups had time constants greater than 2.5 ms and therefore are considered slow currents.
- the midpoint of activation and steady-state inactivation of the TTX-R current was significantly (p ⁇ 0.001) more negative for IB4 + neurons than for LB4 " neurons that produce TTX-R sodium currents (Fig. 5B).
- the midpoint of steady-state inactivation ranged from -31 to -44 mV for TTX-R currents in LB4 + cells and from -25 to -36 mV for TTX-R currents in IB4" cells.
- Fig. 5C shows the distribution of the midpoints of activation and steady-state inactivation for the TTX-R currents.
- IB4 + and IB4 neurons dissociated from adult L4/L5 DRG and cultured for 7 days with normal culture media ("control"), or with media supplemented with NGF, GDNF, BDNF or a combination of NGF and GDNF.
- DRG neurons dissociated and cultured in this manner, in the absence of exogenously added growth factors, have previously been shown to display changes in levels of sodium channel III and SNS/PN3 mRNAs similar to those seen 7 days after nerve transection in vivo (Dib-Hajj et al., 1996; Black et al., 1997).
- GDNF treatment significantly (p c ⁇ 0.01) upregulated SNS/PN3 in both IB4 + and LB4 " neurons (Fig. 6).
- the combination of NGF and GDNF significantly increased the SNS/PN3 hybridization signal in both IB4 + and IB4 " neurons compared to 7 DIV control neurons; however, the signal in IB4 + neurons was less than that observed with either treatment alone, while IB4 " neurons showed similar hybridization signals for the neurotrophins alone or in combination (Fig. 6). In contrast, it was observed that BDNF had no effect on SNS mRNA levels.
- the up-regulation of SNS/PN3 by NGF could be mediated through the trkA pathway; alternatively, the upregulation may be through a pathway involving the p75 receptor.
- K252a in the 100-400 nM range, is a potent inhibitor of NGF action through the trk receptor and has been used to separate effects of NGF mediated through the high- affinity trkA receptor and the low affinity p75 receptor (Kase et al., 1987; Doherty and Walsh, 1989; Tapley et al., 1992; Kahle et al., 1994; Buck and Winter, 1996; De Bernardi et al., 1996).
- GDNF but not NGF, regulates the expression of NaN mRNA, and are consistent with a direct effect of GDNF on sensory neurons that express receptors for the GDNF-family of neurotrophins.
- the hybridization signal in IB4 + neurons treated with the combination of GD ⁇ F and ⁇ GF was somewhat lower than in cultures treated with GD ⁇ F alone (Fig. 9).
- BD ⁇ F had no significant effect on the levels of ⁇ a ⁇ expression compared to control neurons.
- IB4-reactivity in the in situ hybridization experiments was assessed with biotin-labeled IB4 and Cy2-conjugated streptavidin, which provide for enhanced signal amplification. Because of the uncertainty in the IB4-reactivity classification in the patch-clamp experiments on DRG neurons after 7 DIN, sodium current data was not subdivided into IB4 + and LB4- cell groups . Sodium currents were recorded in the presence of 250 nM TTX to isolate TTX-R currents. Figure 11 A shows representative currents for each of the four groups of neurons.
- This reduction in TTX-R currents following in vitro axotomy is very similar to that observed following in vivo axotomy (Cummins and Waxman, 1997).
- TTX-R current expression the percentage of cells expressing TTX-R current amplitudes > 3 nA (Table II) was determined.
- TTX-R currents in neurons at 7 DIV were not made. However, the TTX-R currents in all four groups appeared slow and the midpoints of activation and steady-state inactivation at 7 DIV were generally similar to those observed for IB4 + cells at 1 DIN.
- Example 7 Effect of GDNF and NGF on TTX-R currents in small DRG neurons from SNS-null mice
- Small DRG neurons were taken from SNS-null mice (Akopian et al., 1999) and cultured in vitro using the methods described for rat neurons above. Neurons were cultured in the presence of 250 nM TTX and further in the presence or absence of GDNF (lOng/ml) or NGF (50 ng/ml). The currents were elicited by 200 ms test pulses to potentials ranging from -80 to +40 mV in 5 mV steps. Cells were held at -100 mV. As shown in Figures 12 A, in untreated cultures the persistent non-SNS TTX-R sodium current traces were drastically decreased after 7 days in vitro (7 DIV).
- Example 8 GDNF attenuates the decrease of TTX-R current density and persistent Na + currents in vivo
- K252a modulates the expression of nerve growth factor-dependent capsaicin sensitivity and substance P levels in cultured adult rat dorsal root ganglion neurones. J Neurochem 67:345-351.
- TrkA mediates the nerve growth factor-induced intracellular calcium accumulation. J Biol Chem 35 271:6092-6098.
- K-252a specifically inhibits the survival and morphological differentiation of NGF-dependent neurons in primary cultures of human dorsal root ganglia. Neurosci Lett 96:1-6.
- Nerve growth factor acts through cAMP-dependent protein kinase to increase the number of sodium channels in PC12 cells.
- K-252 compounds novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142:436-440.
- GDNF a glial cell line- derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
- Rizzo MA Kocsis JD, and Waxman SG (1994) Slow sodium conductances of dorsal root ganglion neurons: intraneuronal homogeneity and interneuronal heterogeneity. J Neurophysiol 72:2796-2815. Rizzo MA, Kocsis JD, and Waxman SG (1995) Selective loss of slow and enhancement of fast Na + currents in cutaneous afferent dorsal root ganglion neurons following axotomy. Neurobiol Dis 2:87-96.
- K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7:371-381.
- GDNFR-beta Neurturin and glial cell line-derived neurotrophic factor receptor-beta
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18220/00A AU1822000A (en) | 1998-11-20 | 1999-11-19 | Effects of gdnf and ngf on sodium channels in drg neurons |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10966698P | 1998-11-20 | 1998-11-20 | |
US60/109,666 | 1998-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000030670A1 true WO2000030670A1 (en) | 2000-06-02 |
WO2000030670A9 WO2000030670A9 (en) | 2002-04-25 |
Family
ID=22328892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027368 WO2000030670A1 (en) | 1998-11-20 | 1999-11-19 | Effects of gdnf and ngf on sodium channels in drg neurons |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1822000A (en) |
WO (1) | WO2000030670A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
-
1999
- 1999-11-19 WO PCT/US1999/027368 patent/WO2000030670A1/en active Application Filing
- 1999-11-19 AU AU18220/00A patent/AU1822000A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
Also Published As
Publication number | Publication date |
---|---|
AU1822000A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fjell et al. | Differential role of GDNF and NGF in the maintenance of two TTX-resistant sodium channels in adult DRG neurons | |
Wang et al. | Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain | |
Ylikoski et al. | Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma | |
Sontheimer et al. | Ion channels in spinal cord astrocytes in vitro. I. Transient expression of high levels of Na+ and K+ channels | |
Bron et al. | Activation of Ras is necessary and sufficient for upregulation of vanilloid receptor type 1 in sensory neurons by neurotrophic factors | |
Skoff et al. | Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors | |
Boucher et al. | Neurotrophic factors and neuropathic pain | |
Alvares et al. | Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy | |
Jankowski et al. | Neurotrophic factors and nociceptor sensitization | |
Stucky et al. | Isolectin B4-positive and-negative nociceptors are functionally distinct | |
Lever et al. | Release of BDNF and GABA in the dorsal horn of neuropathic rats | |
Kouranova et al. | Hyperpolarization-activated cyclic nucleotide-gated channel mRNA and protein expression in large versus small diameter dorsal root ganglion neurons: correlation with hyperpolarization-activated current gating | |
Ruiz-Lozano et al. | The molecular basis of neurotrophic keratopathy: diagnostic and therapeutic implications. A review | |
Rodger et al. | cAMP regulates axon outgrowth and guidance during optic nerve regeneration in goldfish | |
von Banchet et al. | Localization of functional calcitonin gene-related peptide binding sites in a subpopulation of cultured dorsal root ganglion neurons | |
Khodorova et al. | The TrkA receptor mediates experimental thermal hyperalgesia produced by nerve growth factor: Modulation by the p75 neurotrophin receptor | |
Lee et al. | Phosphorylation of CREB in axon‐induced Schwann cell proliferation | |
Zeng et al. | Glial Cell–Derived Neurotrophic Factor Enhances Synaptic Communication and 5-Hydroxytryptamine 3a Receptor Expression in Enteric Neurons | |
McIlwrath et al. | Overexpression of neurotrophin‐3 enhances the mechanical response properties of slowly adapting type 1 afferents and myelinated nociceptors | |
Climent et al. | Astrocytes in culture express the full-length Trk-B receptor and respond to brain derived neurotrophic factor by changing intracellular calcium levels: effect of ethanol exposure in rats | |
Bennett et al. | Artemin has potent neurotrophic actions on injured C‐fibres | |
Yao et al. | Targeting proteoglycan receptor PTPσ restores sensory function after spinal cord dorsal root injury by activation of Erks/CREB signaling pathway | |
Wang et al. | GDNF acutely potentiates Ca2+ channels and excitatory synaptic transmission in midbrain dopaminergic neurons | |
Poulsen et al. | Glutamate receptor antagonists and growth factors modulate dentate granule cell neurogenesis in organotypic, rat hippocampal slice cultures | |
Whitlon et al. | Culture conditions determine the prevalence of bipolar and monopolar neurons in cultures of dissociated spiral ganglion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 18220 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09856274 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |